Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy
Back to article page
OriginalPaper|Updated:2021-08-27
|
Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy
Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy
中国结合医学杂志(英文版)2007年13卷第1期 页码:37-40
Affiliations:
Department of Biomedical Engineering, Affiliated Hospital of Guangzhou Medical College,Guangzhou,China
Author bio:
Funds:
Supported by Integrative Medicine Foundation of State Administration of Guangdong Province (No.1050068), Traditional Chinese Medicine Foundation and Integrative Medicine Foundation of Guangzhou City (No.2005A038)
Yang, B., Li, Hs., Qi, Yc. et al. Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy., Chin. J Integ. Med. 13, 37–40 (2007). https://doi.org/10.1007/s11655-007-0037-5
Yang Bo, Li Hong-sheng, Qi Yan-chao, et al. Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy[J]. Chinese Journal of Integrative Medicine, 2007,13(1):37-40.
Yang, B., Li, Hs., Qi, Yc. et al. Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy., Chin. J Integ. Med. 13, 37–40 (2007). https://doi.org/10.1007/s11655-007-0037-5DOI:
Yang Bo, Li Hong-sheng, Qi Yan-chao, et al. Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy[J]. Chinese Journal of Integrative Medicine, 2007,13(1):37-40. DOI: 10.1007/s11655-007-0037-5.
Clinical study on treatment of mammary cancer by Shenqi Fuzheng Injection (参芪 扶正注射液) in cooperation with chemotherapy
摘要
To study the effect of Shenqi Fuzheng Injection (参芪 扶正注射液
SFI) on cellular immune in patients with mammary cancer (MC) after chemotherapy. One hundred and ten patients with MC were randomly assigned to two groups. The 58 patients in the tested group were treated with SFI in cooperation with chemotherapy of CAF protocol (Cyclophosphamide
Doxorubicin and Fluorouracil)
while the 52 patients in the control group were treated with chemotherapy of the same protocol alone. Changes of the patients’ quality of life (QOF)
adverse reaction that occurred
peripheral lymphocyte count and killing activity of single karyocyte before and after treatment between the two groups were compared. Patients’ QOF elevating rate after treatment in the tested group and the control group was 34.5% and 13.5% respectively; The lowering of peripheral blood cell count of WBC
platelet and lymphocyte as well as that of the killing activity of single peripheral karyocyte on various kinds of MC cells were all milder and recovery sooner than those in the control group. SFI in combination with chemotherapy in treating MC could reduce the occurrence of adverse reaction to chemotherapy
improve clinical symptoms
elevate QOF and enhance immunity in patients with MC.
Abstract
To study the effect of Shenqi Fuzheng Injection (参芪 扶正注射液
SFI) on cellular immune in patients with mammary cancer (MC) after chemotherapy. One hundred and ten patients with MC were randomly assigned to two groups. The 58 patients in the tested group were treated with SFI in cooperation with chemotherapy of CAF protocol (Cyclophosphamide
Doxorubicin and Fluorouracil)
while the 52 patients in the control group were treated with chemotherapy of the same protocol alone. Changes of the patients’ quality of life (QOF)
adverse reaction that occurred
peripheral lymphocyte count and killing activity of single karyocyte before and after treatment between the two groups were compared. Patients’ QOF elevating rate after treatment in the tested group and the control group was 34.5% and 13.5% respectively; The lowering of peripheral blood cell count of WBC
platelet and lymphocyte as well as that of the killing activity of single peripheral karyocyte on various kinds of MC cells were all milder and recovery sooner than those in the control group. SFI in combination with chemotherapy in treating MC could reduce the occurrence of adverse reaction to chemotherapy
improve clinical symptoms
elevate QOF and enhance immunity in patients with MC.
Chai KQ, Ying XH. Exploration on the mechanism of vital energy supporting principle in regulating immunity. J Zhejiang Tradit Chin Med Coll 2003; 27(4): 14–15.
Ohtake N, Suzuki R, Daikuhara H, et al. Modulation of lung local immune responses by oral administration of a herbal medicine Sho-saiko-to. Int J Immunopharmacol 2000;22:419–430.
Zhou WS, Liu ZD, Wu LS. Diagnostic and treatment principles of combined traditional Chinese medicine with Western medicine for hepatocellular carcinoma. Bull Chin Cancer 2003; 12(9): 512–514.
Bussiere M, Hopman W, Day A, et al. Indicators of functional status for primary malignant brain tumour patients. Can J Neurol Sci 2005; 32: 50–56.
Yu SZ, Yang GH, Feng JM. Clinical study on treatment of malignant neoplasms with Shenqi Fuzheng Injection and chemotherapy. J Chin Integr Med 2006; 4(1): 84–86.
Wang N, Huang LP. Effect of Shen Qi Fu Zheng Injection on lymphatic cells. Chin J Surg Integr Tradit West Med 2006; 12(2): 139–142.